PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
32934676-9	2020	Colony formation, MTT, FCM assays and animal assays indicated SMYD3 affected the proliferation, apoptosis and the cell cycle of COAD cells in vitro and promoted tumor growth in mice in vivo.	monooxyethylene trimethylolpropane tristearate	18-21	SET and MYND domain containing 3	Mus musculus	62-67
34587977-9	2021	Histone-Lysine N-Methyltransferase SMYD3 was a major epigenetic regulator of INMT expression, treatment with SMYD3 inhibitor BCl-121 suppressed INMT expression and inhibits CRPC development.	bcl-121	125-132	SET and MYND domain containing 3	Mus musculus	0-40
34587977-9	2021	Histone-Lysine N-Methyltransferase SMYD3 was a major epigenetic regulator of INMT expression, treatment with SMYD3 inhibitor BCl-121 suppressed INMT expression and inhibits CRPC development.	bcl-121	125-132	SET and MYND domain containing 3	Mus musculus	109-114
33244033-5	2020	We found that the SMYD3 lysine methyltransferase is spatially redistributed dependent on cell geometry (cell shape and aspect ratio) in murine myoblasts.	Lysine	24-30	SET and MYND domain containing 3	Mus musculus	18-23
33244033-8	2020	The distribution of SMYD3 in response to cell geometry correlated with cytoplasmic and nuclear lysine tri-methylation (Kme3) levels, but not Kme2.	Lysine	95-101	SET and MYND domain containing 3	Mus musculus	20-25
32934676-9	2020	Colony formation, MTT, FCM assays and animal assays indicated SMYD3 affected the proliferation, apoptosis and the cell cycle of COAD cells in vitro and promoted tumor growth in mice in vivo.	Fosfomycin	23-26	SET and MYND domain containing 3	Mus musculus	62-67
17609160-0	2007	SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.	Dexamethasone	66-79	SET and MYND domain containing 3	Mus musculus	0-40
26985287-0	2016	Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.	oxindole sulfonamides	6-27	SET and MYND domain containing 3	Mus musculus	100-105
26985287-0	2016	Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.	sulfamides	32-42	SET and MYND domain containing 3	Mus musculus	100-105
26985287-0	2016	Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.	EPZ031686	44-53	SET and MYND domain containing 3	Mus musculus	100-105
26985287-2	2016	A novel oxindole series of SMYD3 inhibitors was identified through screening of the Epizyme proprietary histone methyltransferase-biased library.	2-oxindole	8-16	SET and MYND domain containing 3	Mus musculus	27-32
26985287-3	2016	Potency optimization afforded two tool compounds, sulfonamide EPZ031686 and sulfamide EPZ030456, with cellular potency at a level sufficient to probe the in vitro biology of SMYD3 inhibition.	fusarubin	76-85	SET and MYND domain containing 3	Mus musculus	174-179
31968646-6	2020	Furthermore, using an oleic acid-induced hepatocyte steatosis model, we found that HMGCR can be directly transactivated by SET and MYND domain containing 3 (SMYD3), a transcriptional regulator, via 5"-CCCTCC-3" element in the promoter.	Oleic Acids	22-32	SET and MYND domain containing 3	Mus musculus	123-155
31968646-6	2020	Furthermore, using an oleic acid-induced hepatocyte steatosis model, we found that HMGCR can be directly transactivated by SET and MYND domain containing 3 (SMYD3), a transcriptional regulator, via 5"-CCCTCC-3" element in the promoter.	Oleic Acids	22-32	SET and MYND domain containing 3	Mus musculus	157-162
31968646-8	2020	To the best of our knowledge, this study is the first to illustrate that COS mediate glucose and lipid metabolism disorders by regulating gut microbiota and SMYD3-mediated signaling pathways.	Glucose	85-92	SET and MYND domain containing 3	Mus musculus	157-162
23752591-6	2013	Supporting functional relevance of the SMYD3/BRD4 interaction, BRD4 pharmacological blockade by the small molecule JQ1 prevents dexamethasone-induced myostatin and atrogene up-regulation and spares myotube atrophy.	Dexamethasone	128-141	SET and MYND domain containing 3	Mus musculus	39-44
23752591-7	2013	Importantly, in a mouse model of dexamethasone-induced skeletal muscle atrophy, SMYD3 depletion prevents muscle loss and fiber size decrease.	Dexamethasone	33-46	SET and MYND domain containing 3	Mus musculus	80-85
17609160-5	2007	The SMYD3-gene-transfected cells showed an increased proliferation rate and became more resistant to cell death induced by dexamethasone.	Dexamethasone	123-136	SET and MYND domain containing 3	Mus musculus	4-9